| abstract |
Bispecific binding molecules that bind both Dll4 and Ang2, preferably in the form of immunoglobulin single variable domains, such as VHH and domain antibodies, pharmaceutical compositions comprising said, and Dll4-mediated in angiogenesis Disclosed are their use in the treatment of diseases closely related to effects and / or Ang2-mediated effects. Furthermore, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing the same are also disclosed. |